DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally?

Decoy Therapeutics has secured funding to begin clinical trials for its programs targeting respiratory illnesses.

• The company has received $3.5 million from an unnamed institutional investor through a private placement.
• Additional funding can be secured from the investor if certain milestones are achieved.
• Decoy is currently working on a nasal-based therapy that can cure all kinds of coronaviruses and a “tripledemic” vaccine that can protect against flu, coronaviruses, and respiratory syncytial viruses.

Shares of Decoy Therapeutics (DCOY) soared on Monday after the company secured up to $21 million to fund clinical trials of its lead programs targeting respiratory viral illnesses.

At the time of writing, DCOY stock was up more than 84%.

DCOY Secures Milestone-Based Funding

According to an SEC filing, the company has secured funding from an unnamed institutional investor through a private placement offering, under which Decoy sold 592,217 shares at $5.97 per share, raising $3.5 million.

The investor was also issued milestone-based Series A, Series B, and Series C common warrants, exercisable upon the company's achievement of certain targets. Proceeds from warrant redemptions would be an additional $17.5 million.

What Milestones Is DCOY Targeting?

The company will be able to receive an additional $3.5 million in funding from Series A warrants, when exercised, once it applies to begin Phase 1 trials in Europe. It will receive $7 million from Series B warrants once the U.K. health regulator greenlights its Phase 2a human challenge trial, and another $7 million from Series C warrants if the early-stage U.K. trial is successful.

According to the company, it is focused on Designable Multi-Antivirals (D-MAVs), which aim to enable a single drug to work against multiple viral threats, to evolve from the traditional one-virus, one-drug model.

Decoy is currently working on a nasal-based therapy that can cure all kinds of coronaviruses and a “tripledemic” vaccine that can protect against flu, coronaviruses, and respiratory syncytial viruses.

What Do Retail Traders Think About DCOY?

On Stocktwits, retail sentiment on DCOY turned ‘extremely bullish’ from ‘neutral’ over the last 24 hours.

DCOY stock has declined more than 29% so far this year and more than 91% over the last 12 months, underperforming the S&P 500.

For updates and corrections, email newsroom[at]stocktwits[dot]com<